Therefore, enzalutamide in monotherapy in men with previously untreated prostate cancer produces an adequate level of suppression of the disease as measured by a long and sustained decrease in PSA with less toxicity than LH-RH agonists (26). The gene discussed is KLK3; the disease is prostate carcinoma.